Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)
| Autor: | Lee, Hun Ju, Abramson, Jeremy S., Bartlett, Nancy L. *, Burke, John M., Lynch, Ryan C. *, Eva, Domingo Domenech *, Hess, Brian T., Schuster, Steven R. *, Linhares, Yuliya *, Ramchandren, Rod, Gandhi, Mitul, Mowat, Rex *, Shah, Harsh, Rossi, Giuseppe, Hahn, Uwe H *, Prince, Henry Miles *, Ho, Linda, Guo, Wenchuan *, Yasenchak, Christopher A., Straus, David J. |
|---|---|
| Zdroj: | In Blood 15 November 2022 140 Supplement 1:9399-9401 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|